Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000082174 | SCV000114120 | benign | not specified | 2012-11-15 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000082174 | SCV000151161 | benign | not specified | 2013-12-30 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000082174 | SCV000269110 | benign | not specified | 2015-01-13 | criteria provided, single submitter | clinical testing | p.Ala83Ala in exon 4 of FKRP: This variant is not expected to have clinical sign ificance because it does not alter an amino acid residue and is not located with in the splice consensus sequence. It has been identified in 1.3% (115/8570) of E uropean American chromosomes from a broad population by the NHLBI Exome Sequenci ng Project (http://evs.gs.washington.edu/EVS; dbSNP rs149030303). |
Labcorp Genetics |
RCV000233707 | SCV000290696 | benign | Walker-Warburg congenital muscular dystrophy | 2025-02-04 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000082174 | SCV000314265 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Gene |
RCV000082174 | SCV000513038 | benign | not specified | 2015-05-12 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
ARUP Laboratories, |
RCV001725965 | SCV001471814 | benign | not provided | 2023-10-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002426645 | SCV002740941 | benign | Cardiovascular phenotype | 2019-01-25 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV002483151 | SCV002794952 | likely benign | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1; Muscular dystrophy-dystroglycanopathy type B5; Autosomal recessive limb-girdle muscular dystrophy type 2I; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A5 | 2021-08-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000082174 | SCV003928577 | benign | not specified | 2023-04-17 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001725965 | SCV005310991 | benign | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001272537 | SCV001454627 | benign | Autosomal recessive limb-girdle muscular dystrophy type 2I | 2020-09-16 | no assertion criteria provided | clinical testing | |
Clinical Genetics, |
RCV000082174 | SCV001921550 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001725965 | SCV001964330 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV000082174 | SCV002036545 | benign | not specified | no assertion criteria provided | clinical testing |